Table 3. Optimal detected targets combined with their prescription drugs for the multiobjective drug discovery problem to remedy the most severe dopamine deficiency.

Disease	T*	A*	V*	Detected target	Specified target (Prescription drugs)
VM95	0.574	0.611	0.574	α13, α15, α16, α60	—
	0.425	0.493	0.425	α13, α15	ut (Diet control)
	0.588	0.588	0.588	α13, α15, α31, α60	ul (Madopar, Sinemet)
	0.605	0.605	0.605	α13, α15, α31, α61	ud (Bromocriptine, Pergolide, Pramipexole, Ropinirole)
	0.626	0.626	0.626	α13, α15, α31, α61	α22, α26 (Entacapone, Tolcapone)
	0.576	0.611	0.576	α13, α16, α60	α15, α23, α24 (Selegiline, Rasagiline)
TH100	0.651	0.588	0.588	α2, α8, ut, ul, ud	—
	0.651	0.588	0.588	α2, α8, ul, ud	ut (Diet control)
	0.651	0.588	0.588	α2, α8, ut, ud,	ul (Madopar, Sinemet)
	0.651	0.588	0.588	α2, α8, ut, ul	ud (Bromocriptine, Pergolide, Pramipexole, Ropinirole)
	0.503	0.682	0.508	α2, α8, ut, ul	α22, α26 (Entacapone, Tolcapone)
	0.637	0.637	0.637	α2, α8, ut, ul, ud	α15, α23, α24 (Selegiline, Rasagiline)

The current prescription drugs for PD treatment are shown in parentheses. VM95 reflect 95% deficiency of VMAT2 and TH100 indicate 100% deficiency of TH. Furthermore, u_t, u_l, and u_d denote the external control for tyrosine, L-DOPA, and intracellular dopamine, respectively. α_j is the enzyme activity for the j^th reaction rate. T, A, and V denote the satisfaction grade for therapeutic, adverse, and variation effects, respectively.

* indicates the optimal solution.